Every letter we have printed

The residual moisture point is the one I would put in bold. A cake dried to one per cent water and a cake dried to four behave entirely differently over a year at the same temperature, and the certificate reports neither. Of every determination available to this trade, water content is the cheapest and the most predictive of shelf life.

An excipient note. Mannitol crystallises and gives a firm elegant cake with poor protection; sucrose stays amorphous and protects rather better while looking worse. Buyers judge cakes by appearance, and appearance and stability are pulling in opposite directions.

Aggregation is not degradation in the chemical sense and it is reported as though it were. The molecule is intact and its physical state has changed, which is a different problem with different consequences.

Adsorption to the container is under-appreciated. At low concentrations a meaningful fraction of peptide can be lost to the glass or the plastic within hours, which looks exactly like degradation and is not. It is also the reason a dilute working solution behaves worse than a concentrated one.

Accelerated stability studies assume the same pathway dominates at elevated temperature as at storage temperature, and for peptides that assumption fails often enough to matter. Extrapolated shelf lives should be treated as estimates.

The most reported response in every account I have collected is to wait, and waiting is not described as a strategy in any formal source. The commonest behaviour in the field has no name in the literature.

Schedule adjustment is discussed everywhere and studied nowhere, and it interacts directly with the exposure profile in ways the pharmacology department has covered well. The two discussions belong in the same article.

Tachyphylaxis in the emptying effect is a real observation and it is the mechanistic basis for symptoms easing at a stable dose. Stating it explicitly would help readers understand why the advice is to hold rather than to stop.

Rapid weight change mobilises material stored in adipose tissue, and analytes that partition there behave accordingly. Reading such a movement as new pathology rather than as redistribution is an easy error and your piece describes it well.

Haemoconcentration is the artefact I would put first. A modest change in plasma volume shifts every concentration on the panel in the same direction at once, and the pattern is unmistakable if you look at the whole report rather than at the flagged line.

Ferritin is an acute phase reactant, so a value taken during inflammation says something about the inflammation. Pairing it with a marker that is not acute phase is the standard remedy and it is routinely omitted.

Anything that shortens red cell survival lowers the result independently of glycaemia. Haemoglobin variants interfere with some assay methods and not others. These are not exotic situations, and a value that does not fit the clinical picture deserves a different measurement rather than a firmer conclusion.

A modest proposal: publish the shipping cost alongside the result. It sounds irrelevant and it is the fastest way for a reader to tell a genuine retail purchase from a sample that arrived by arrangement.

An observation from the receiving end. When we are sent numbered samples with no context we ask more questions of the data, because we cannot lean on an expectation. Blinding improves the analysis as well as the credibility, and that argument is never made.

I would add that a genuine chromatogram is far harder to fabricate than a summary page, which is why the summary page is what circulates. A seller who attaches the instrument output is telling you something about their confidence before you read a single number on it.

The cloned-template problem is easy to detect and nobody does the detecting. Identical column identifiers, identical retention times to two decimals and different product names across four documents is not a coincidence, and it takes one careful reading to see. Buyers do not read certificates; they file them.

The question I have learned to ask first is who commissioned the test. A certificate paid for by the seller, a certificate paid for by the buyer and a certificate paid for by a third party at the seller’s request are three different documents, and only one of them names the arrangement on its face.

Your ten-minute check told me in about ninety seconds that the batch number on my certificate appears nowhere on the vial. I wrote to the supplier and had a straightforward answer within a day: the certificate covers the bulk lot and the vial carries a fill code. I would never have known to ask.

Weight loss of any origin is associated with density change, so the comparator matters enormously. Without a matched non-pharmacological arm, an observed change tells you about losing weight rather than about the agent.

Site matters enormously. Spine, hip and forearm measurements diverge in the same individual over the same period, and a single reported figure without the site is close to uninterpretable.

Your comparison of the printed schedules across agents shows how much variation there already is between products, which undercuts the idea that any one schedule is uniquely correct. It would be worth stating the doses in the table with the intervals rather than beside them.

Divergence between practice and label is used as an argument in both directions and supports neither. That people do something differently is a fact about people, and it carries no information about whether it works.

The four-week interval is not arbitrary and your article explains why better than the labels do. With a half-life of about a week, four weeks is roughly the time to steady state, so a shorter interval escalates onto a concentration that has not finished rising. That is the arithmetic, and it deserves to be quoted whenever the interval is questioned.

The studied interval was chosen partly for adherence, and adherence in a trial is measured and supported in ways it is not outside one. A schedule that works in a study population may not survive contact with an ordinary week.

Thank you for printing the letters that disagree with the desk at the same length as the ones that do not. It is a small editorial choice with a large effect on how the column reads.

Precision error on a densitometer is a published figure for each machine and it is comparable in size to the changes being reported. Any study reporting a change smaller than its own least significant change is reporting noise, and some do.

Fracture is the endpoint that matters and no study in this area is remotely powered for it. Everything published is a surrogate, and the relationship between the surrogate and the outcome is itself an active research question.

I train four times a week, eat a hundred and sixty grams of protein and my appendicular lean mass has fallen by 1.8 kg over ten months while every lift has gone up. Your section on mass against function was the first thing I have read that made that seem normal rather than a failure.

The unit confusion in this area is a design problem rather than an education problem. A syringe graduated for one purpose, used to measure a volume of something else, will produce errors at a rate determined by the markings and not by the diligence of the person reading them.

Please keep printing the conversion in both directions. Readers can usually go from concentration to volume and stumble going back from a marking to a mass, and the second direction is the one that matters when somebody is checking what they did rather than planning it.

Colour is doing unearned work. Green reads as approved in every other context a shopper encounters, and a service that renders an ordinary numeric result in the vocabulary of a safety certification has borrowed authority it did not generate.

Retailers who buy from wholesalers display the wholesaler’s badge. The mark then describes material two steps removed from the vial being sold, and every party in the chain has behaved reasonably. Aggregation is where most of the misleading happens and no rule addresses it.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

A withdrawal design also measures the effect of the surrounding programme falling away. Participants lose the visits, the monitoring and the contact at the same moment they lose the drug, and no published design separates those.

Blinding a withdrawal is harder than blinding an initiation, for reasons that are obvious once stated: the effects being withdrawn are perceptible. Any withdrawal trial reporting successful blinding should be asked how it was assessed.

The dose that produced the change and the dose that holds it need not be the same, and the pharmacology gives no strong reason to assume they are. That is a hypothesis worth testing and at present it is being tested informally by a great many people.

What is not studied at all is what happens when somebody maintains for years and then has to stop for reasons outside their control. Every account of stopping in the literature is a planned stop, and planned stops are the minority case here.

Whatever is decided, the most useful thing anybody can do is write down the date of the last dose and what happened over the following weeks. The observational record in this area is poor mainly because nobody keeps one.

You ask what a batch number should look like. In my experience the useful convention encodes the date and the campaign, so that a buyer can tell whether two vials bought six months apart came from the same synthesis. A serial with no structure is a label; a structured one is a small piece of traceability given away free.